ArticleFrontiers in immunology2025
Temporal trends in malignancy incidence and outcomes among kidney transplantation recipients: a multi-center real-world evidence study using the TriNetX network (2000-2010 vs. 2010-2021).
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating the Role of Basiliximab Induction in Simultaneous Liver-Kidney Transplantation: A Multicenter Propensity-Score-Matched Analysis.Antibodies (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abbreviations: BMI, body mass index; CI, confidence interval; ESRD, end stage renal disease; HR, hazard ratio; IRB, Institutional Review Board; ICD, International Classification of Diseases; KTX, kidney transplantation; mTOR, mammalian target of rapamycin; PSM, propensity scoring matching; PTM: post-transplantation malignancy; SIR, standardized incidence ratio; SMR, standardized mortality rate. Objective: Malignancy is a main cause of mortality and morbidity in kidney transplantation recipients. Advancements in cancer surveillance and treatment may contribute to increased incidence and improved clinical outcomes. This study aimed to investigate the trends and clinical outcomes of post-transplantation malignancies over the past two decades. Methods: We conducted a retrospective cohort study using the TriNetX network. Common post-transplantation malignancies were identified, and outcomes were assessed using Kaplan-Meier survival analysis with propensity score matching. We compared two transplantation cohorts (2000-2010 and 2011-2021) to assess potential changes in malignancy incidence, graft survival, and patient mortality. Results: A total of 184,267 kidney transplantation recipients were included. Compared to the general population, transplantation recipients exhibited a higher risk of malignancy [standardized incidence ratio (SIR) 1.635; 95% confidence interval (CI), 1.600-1.670] and mortality [hazard ratio (HR) 1.115; 95% CI, 1.071-1.763; Conclusion: Kidney transplantation recipients remain at increased risk for malignancies and associated mortality. While the incidence of malignancies has not changed significantly over the past two decades, both graft failure and mortality have declined in the recent decade, potentially reflecting improvements in post-transplantation care and cancer management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.